UNCOVER – Universal CRISPR-based Detection Platform for Versatile and Rapid Diagnostics
nSAGE, Caszyme, and Vilnius University have joined forces to form a consortium which will develop a new, advanced diagnostics solution. The UNCOVER project will develop a universal, CRISPR-based diagnostics platform for accurate and rapid detection of infectious diseases. This platform will be versatile, user-friendly, applicable to both human and animal health, and will be easily programable to address a wide range of pathogens and disease biomarkers.
UNCOVER will utilize advanced bioinformatics and protein engineering technologies, with the consortium planning to discover novel and optimise existing Cas proteins to improve their sensitivities and specificities.
The platform will undergo validation with patient samples and will address a critical gap in Point-of-Care diagnostics thus advancing local and global disease detection capabilities.
Project start: April 1st, 2025
Project duration: 36 months
The UNCOVER project is co-funded by the European Union (Eurostars project No.7803) under the agreement with the Research Council of Lithuania (LMTLT).
Eurostars is the largest funding programme of the European Commission that supports innovative SMEs in developing collaborative transnational projects geared towards the market. The programme is part of Horizon Europe and is managed by Eureka with a network of national coordinators from the 37 participating countries.